Spero Therapeutics, Inc.
SPRONasdaqCIK 1701108HealthcareFiscal year ends Dec 31
Reports and events: 174 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2018-09-2716:08 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-18-285631 |
| 2018-08-1408:09 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-18-247901 |
| 2018-08-0916:21 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-18-244366 |
| 2018-08-0916:01 ET | 10-Q | Quarterly reportPeriod 2018-06-30 | 0001564590-18-021018 |
| 2018-07-1716:31 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-18-219722 |
| 2018-07-1607:13 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-18-218281 |
| 2018-07-1117:30 ET | S-1/A | Registration statement, amended | 0001193125-18-216210 |
| 2018-07-0916:21 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-18-214735 |
| 2018-07-0916:05 ET | S-1 | Registration statement | 0001193125-18-214717 |
| 2018-07-0907:38 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-18-214220 |
| 2018-06-0816:01 ET | 8-K | 5.07 Shareholder vote results | 0001193125-18-188029 |
| 2018-05-1016:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-18-159225 |
| 2018-05-1016:03 ET | 10-Q | Quarterly reportPeriod 2018-03-31 | 0001564590-18-012933 |
| 2018-04-2708:20 ET | DEF 14A | Proxy statementPeriod 2018-06-05 | 0001193125-18-136751 |
| 2018-04-0217:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-18-104993 |
| 2018-04-0216:02 ET | 10-K | Annual reportPeriod 2017-12-31 | 0001564590-18-007402 |
| 2018-03-1416:30 ET | SC 13D | Ownership report, active investor | 0001144204-18-014661 |
| 2018-02-0108:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-18-028379 |
| 2018-01-2308:00 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-18-016749 |
| 2017-12-1416:25 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-17-369517 |
| 2017-12-1416:03 ET | 10-Q | Quarterly reportPeriod 2017-09-30 | 0001193125-17-369457 |
| 2017-11-0616:23 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-17-334318 |
| 2017-10-2310:31 ET | S-1/A | Registration statement, amended | 0001193125-17-315961 |
| 2017-10-0616:13 ET | S-1 | Registration statement | 0001193125-17-305888 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 13, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.